Magna Diagnostics GmbH, a subsidiary of Bioville GmbH is developing an innovative diagnostic platform for fast, simple and inexpensive point-of-care diagnosis of infectious diseases. Bioville GmbH advises primarily foreign companies who are interested in relocating and appling for funds in Saxony.
The partnership structure of Bioville GmbH consists of Dr. Christian Zilch, Dr. Wilhelm Gerdes, Dr. Sonya Faber, MBA and Bernhard Faber LL.M. Bioville GmbH in turn is 100% shareholder of Magna Diagnostics GmbH.
Magna Diagnostics GmbH had since mid 2010 been the coordinator of a 2.2 million € BMBF project (MinoLab) and also participated in a large EU-project named e-BRAINS, which was coordinated by Infineon AG. In 2014, the first functional prototypes of its MAZER platform were presented. Magna Diagnostics GmbH provided significant co-financing for its shares over the project period. In addition, Magna Diagnostics GmbH has two other confidential projects in the pipeline which represent interesting investment opportunities. Magna Diagnostics now seeks further capital in order to transfer clinically relevant assays to its MAZER platform and to prepare all necessary steps for the validation and IVD-registration of its diagnostic system
Bioville GmbH as a 100% owner of Magna Diagnostics GmbH is willing to sell shares to an investor to a maximum of 24.9% of the total shares. Alternatively, Bioville GmbH is willing to offer potential investors a convertible loan to be repaid at the conclusion of a set period. This version includes a vested claim on the side of the lender to repayment and interest at the end of the term which can be converted into a business stake in Magna Diagnostics GmbH.
If interested, potential buyers can always contact us.